A biotech's focus on developing a drug for the chronic disease gets a boost from new, positive data.
Investors await the Federal Reserve policy decision and more key quarterly results.
US markets set to open unchanged as the Federal Reserve is to begin its 2-day policy meeting.
Amgen, Celgene and Pharmacyclics see short interest drop recently.
Baidu is upgraded to 'buy,' and Health Management is downgraded to 'hold.'
There's mixed interest in biotech, biopharmaceutical and emerging pharma companies.
VIDEO ON MSN MONEY
Copyright © 2013 Microsoft. All rights reserved.
Quotes are real-time for NASDAQ, NYSE and AMEX. See delay times for other exchanges.
Fundamental company data and historical chart data provided by Thomson Reuters (click for restrictions). Real-time quotes provided by BATS Exchange. Real-time index quotes and delayed quotes supplied by Interactive Data Real-Time Services. Fund summary, fund performance and dividend data provided by Morningstar Inc. Analyst recommendations provided by Zacks Investment Research. StockScouter data provided by Verus Analytics. IPO data provided by Hoover's Inc. Index membership data provided by SIX Financial Information.
Stocks are higher as the Dow looks to extend its streak of consecutive Tuesday advances -- it hasn't finished lower on a Tuesday since January 8.
The Market Dispatches column has been discontinued. Here's where to find the latest stock and business news on MSN Money, and the latest from market writer Charley Blaine.
MONEY & POLITICS
Breaking up big banks is an untested solution to the too big to fail problem that attempts to isolate and dismantle large, troubled institutions while protecting the rest of the economy.
The IRS is struggling to combat identify thieves who file fraudulent tax returns in the names of older residents who don't need to file.